Concurrent administration of liposomal doxorubicin improves the survival of patients with invasive bladder cancer undergoing hypofractionated accelerated radiotherapy (HypoARC)

Medical Oncology

Volumn 28, Issue 4, 2011, Pages 1356-1362

  Panteliadou, Marianthi ^a   Touloupidis, Stavros ^a   Giatromanolaki, Alexandra ^b   Pistevou, Kiriaki ^c   Kyrgias, George ^d   Tsoutsou, Pelagia ^a   Kalaitzis, Christos ^a   Koukourakis, Michael I ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d UNIVERSITY OF THESSALY   (Greece)

Author keywords

Amifostine; Bladder cancer; Liposomal doxorubicin; Radiotherapy

Indexed keywords

AMIFOSTINE; DOXORUBICIN;

ADULT; AGED; ARTICLE; BACKACHE; BLADDER CANCER; BLADDER DISEASE; BLOOD TOXICITY; CANCER CONTROL; CANCER INVASION; CANCER RELAPSE; CANCER SURVIVAL; COLITIS; CONTROLLED STUDY; DIARRHEA; DRUG DOSE INCREASE; DRUG TOLERABILITY; DYSPNEA; DYSURIA; FEMALE; FLUSHING; HAND FOOT SYNDROME; HUMAN; HYPOFRACTIONATED ACCELERATED RADIOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROCTITIS; RADIOTHERAPY; RECURRENCE FREE SURVIVAL; SIDE EFFECT; SKIN TOXICITY; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, TRANSITIONAL CELL; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; DOXORUBICIN; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIPOSOMES; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; RADIOTHERAPY; URINARY BLADDER NEOPLASMS;

EID: 84655170315     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9544-x     Document Type: Article

References (14)

1. CM Coppin MK Gospodarowicz K James IF Tannock B Zee J Carson J Pater LD Sullivan 1996 Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 14 2901 2907
2. HW Herr DF Bajorin HI Scher 1998 Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome J Clin Oncol 16 1298 1301
3. WU Shipley KA Winter DS Kaufman WR Lee NM Heney WR Tester BJ Donnelly PM Venner CA Perez KJ Murray RS Doggett LD True 1998 Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03 J Clin Oncol 16 3576 3583
4. Advanced Bladder Cancer (ABC) 2005 Meta-analysis collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration Eur Urol 48 202 205
5. JA Efstathiou K Bae WU Shipley DS Kaufman MP Hagan NM Heney HM Sandler 2009 Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06 J Clin Oncol 27 4055 4061
6. RH Mak AL Zietman NM Heney DS Kaufman WU Shipley 2008 Bladder preservation: optimizing radiotherapy and integrated treatment strategies BJU Int 102 1345 1353
7. MI Koukourakis S Koukouraki A Giatromanolaki SC Archimandritis J Skarlatos K Beroukas JG Bizakis G Retalis N Karkavitsas ES Helidonis 1999 Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer J Clin Oncol 17 3512 3521
8. MI Koukourakis S Koukouraki A Giatromanolaki S Kakolyris V Georgoulias A Velidaki S Archimandritis NN Karkavitsas 2000 High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas-rationale for combination with radiotherapy Acta Oncol 39 207 211
9. MI Koukourakis C Tsolos S Touloupidis 2007 Radical hypofractionated accelerated radiotherapy with cytoprotection for invasive bladder cancer Urology 69 245 250
10. MI Koukourakis I Abatzoglou L Sivridis M Tsarkatsi H Delidou 2006 Individualization of the subcutaneous amifostine dose during hypofractionated/accelerated radiotherapy Anticancer Res 26 2437 43
11. HB Grossman RB Natale CM Tangen VO Speights NJ Vogelzang DL Trump RW deVere White MF Sarosdy DP Wood Jr D Raghavan ED Crawford 2003 Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer N Engl J Med 349 859 866
12. E Winquist DS Ernst D Jonker MJ Moore R Segal G Lockwood A Rodgers 2003 Phase II trial of pegylated-liposomal doxorubicin in the treatment of locally advanced unresectable or metastatic transitional cell carcinoma of the urothelial tract Eur J Cancer 39 1866 1871
13. MI Koukourakis J Manavis C Simopoulos V Liberis A Giatromanolaki E Sivridis 2005 Hypofractionated accelerated radiotherapy with cytoprotection combined with trastuzumab, liposomal doxorubicine, and docetaxel in c-erbB-2-positive breast cancer Am J Clin Oncol 28 495 500
14. BJ Brooks Jr EJ Seifter TE Walsh AS Lichter PA Bunn A Zabell A Johnston-Early M Edison RW Makuch MH Cohen 1986 Pulmonary toxicity with combined modality therapy for limited stage small-cell lung cancer J Clin Oncol 4 200 209